The effect of MMR vaccine in preventing Covid disease 19

Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200802048266N1

Enrollment

323

Registered

2020-09-22

Start date

2020-11-19

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Health workers exposed to the epidemic virus (COVID-19) who were randomly selected after registering personal information including name, gender, age, weight, plac

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ahvaz health personnel with the age of 25-65 years

Exclusion criteria

Exclusion criteria: People with defective immune systems MMR vaccine susceptibility Taking immunosuppressive drugs such as corticosteroids Pregnant women People who are not allowed to get the MMR vaccine People who have active cancer and are receiving chemotherapy or radiotherapy. People who have had an organ transplant and are receiving immunosuppressive drugs. People with active HIV infection .

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: The beginning of the study. Method of measurement: kilograms.;WBC. Timepoint: At the beginning and end of the study. Method of measurement: Flow cytometry.;Lymphocyte count / percentage in CBC. Timepoint: At the beginning and end of the study. Method of measurement: Flow cytometry.;Anti measles antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti rubella antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti mumps antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti SARS-CoV-2 IgG & IgM. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;PCR test. Timepoint: At the beginning and end of the study. Method of measurement: RT-PCR test using nasopharyngeal swabs.;Reduce the need for intubation. Timepoint: At the beginning and end of the study. Method of measurement: View.;Mortality rate. Timepoint: At the beginning and end of the study. Method of measurement: View.	—

Measure

Time frame

Weight. Timepoint: The beginning of the study. Method of measurement: kilograms.;WBC. Timepoint: At the beginning and end of the study. Method of measurement: Flow cytometry.;Lymphocyte count / percentage in CBC. Timepoint: At the beginning and end of the study. Method of measurement: Flow cytometry.;Anti measles antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti rubella antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti mumps antibody titer. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;Anti SARS-CoV-2 IgG & IgM. Timepoint: At the beginning and end of the study. Method of measurement: Eliza test.;PCR test. Timepoint: At the beginning and end of the study. Method of measurement: RT-PCR test using nasopharyngeal swabs.;Reduce the need for intubation. Timepoint: At the beginning and end of the study. Method of measurement: View.;Mortality rate. Timepoint: At the beginning and end of the study. Method of measurement: View.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSouri Heidari

Ahvaz University of Medical Sciences

Sourihedari@yahoo.com+98 61 3336 0289

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026